Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients With Advanced Unresectable Solid Tumors

Next Previous
Trial Profile

A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients With Advanced Unresectable Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plixorafenib (Primary) ; Cobicistat
  • Indications Colorectal cancer; Glioma; Malignant melanoma; Neuroendocrine tumours; Ovarian cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Novellus Biopharma; Plexxikon

Most Recent Events

  • 30 Apr 2025 Results (n=71) from the the analysis of longitudinal ctDNA from plixorafenib-treated pts, an exploratory endpoint from this Phase 1/2a study presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 25 Apr 2025 Results presented in the Fore Biotherapeutics Media Release
  • 25 Mar 2025 According to Fore Biotherapeutics media release, company announced that abstract regarding this trial has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top